The EMEA has approved the production of Myozyme® at the 4000L bioreactor scale at its manufacturing facility in Geel, Belgium. Sales are expected to accelerate starting in the second quarter and continue to increase throughout the second half of the year. Genzyme expects Myozyme sales for the first quarter of 2009 to be similar to the fourth quarter of 2008.